The clinical development process for a novel preventive vaccine: An overview

Area of Science:

• Vaccinology
• Clinical Trial Design
• Regulatory Science

Background:

• Novel vaccine candidates require thorough evaluation for safety, immunogenicity, and protective efficacy before human use.
• Post-initial safety assessment, vaccine development follows distinct pathways guided by international regulatory standards.

Purpose of the Study:

• To provide a comprehensive overview of the clinical development pathway for novel vaccine candidates.
• To outline the expectations of major regulatory bodies, including the World Health Organization (WHO), European Medicines Agency (EMA), and United States Food and Drug Administration (USFDA).

Main Methods:

• Description of clinical trial phases (Phase I-III), including objectives, populations, designs, sites, and outcomes.
• Case studies illustrating the development of vaccines for malaria, rotavirus, and human papillomavirus (HPV).
• Tabulation of relevant international guidelines for vaccine development.

Main Results:

• Detailed explanation of the sequential phases of vaccine clinical development.
• Illustrative examples demonstrating practical application of development pathways.
• Consolidated reference of key regulatory guidelines.

Conclusions:

• Adherence to established clinical trial phases and regulatory guidelines is crucial for successful vaccine development.
• Understanding these pathways ensures comprehensive evaluation of vaccine candidates.
• The article serves as a valuable resource for navigating vaccine development processes.